MX357834B - Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal. - Google Patents

Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal.

Info

Publication number
MX357834B
MX357834B MX2014008875A MX2014008875A MX357834B MX 357834 B MX357834 B MX 357834B MX 2014008875 A MX2014008875 A MX 2014008875A MX 2014008875 A MX2014008875 A MX 2014008875A MX 357834 B MX357834 B MX 357834B
Authority
MX
Mexico
Prior art keywords
compounds
muscular atrophy
spinal muscular
treating spinal
treating
Prior art date
Application number
MX2014008875A
Other languages
English (en)
Other versions
MX2014008875A (es
Inventor
Chen Guangming
Mitchell Karp Gary
Li Chunshi
Narasimhan Jana
Naryshkin Nikolai
L Weetall Marla
Welch Ellen
Dakka Amal
Zhao Xin
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of MX2014008875A publication Critical patent/MX2014008875A/es
Publication of MX357834B publication Critical patent/MX357834B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems

Abstract

Se proporcionan en la presente compuestos, composiciones del mismo y usos con los mismos para tratar la atrofia muscular espinal.
MX2014008875A 2012-01-26 2013-01-25 Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal. MX357834B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261591102P 2012-01-26 2012-01-26
PCT/US2013/023067 WO2013112788A1 (en) 2012-01-26 2013-01-25 Compounds for treating spinal muscular atrophy

Publications (2)

Publication Number Publication Date
MX2014008875A MX2014008875A (es) 2014-10-14
MX357834B true MX357834B (es) 2018-07-26

Family

ID=48873933

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014008875A MX357834B (es) 2012-01-26 2013-01-25 Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal.

Country Status (13)

Country Link
US (1) US9399649B2 (es)
EP (1) EP2809322B9 (es)
JP (2) JP6193888B2 (es)
KR (1) KR102064624B1 (es)
CN (1) CN104203239B (es)
BR (1) BR112014018027B1 (es)
CA (1) CA2862084C (es)
EA (1) EA028344B1 (es)
ES (1) ES2733644T3 (es)
HK (1) HK1202069A1 (es)
MX (1) MX357834B (es)
PL (1) PL2809322T3 (es)
WO (1) WO2013112788A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014016287B1 (pt) 2011-12-30 2022-08-09 F. Hoffmann - La Roche Ag Composto e composição farmacêutica
CN104203239B (zh) * 2012-01-26 2017-09-08 Ptc医疗公司 用于治疗脊髓性肌萎缩的化合物
TR201813877T4 (tr) 2012-02-10 2018-11-21 Hoffmann La Roche Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
US9371336B2 (en) 2012-03-01 2016-06-21 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
KR102109992B1 (ko) 2012-03-23 2020-05-13 피티씨 테라퓨틱스, 인크. 척수성 근위축증을 치료하기 위한 화합물
AU2013368805A1 (en) * 2012-12-24 2015-08-13 Ramot At Tel-Aviv University Ltd. Agents for treating genetic diseases resulting from nonsense mutations, and methods for identifying the same
WO2015024876A2 (en) 2013-08-19 2015-02-26 F. Hoffmann-La Roche Ag Screening method
WO2015095446A1 (en) * 2013-12-19 2015-06-25 Ptc Therapeutics, Inc. Methods for modulating the amount of rna transcripts
WO2015105657A1 (en) 2013-12-19 2015-07-16 Ptc Therapeutics, Inc. Methods for modulating the amount of rna transcripts
US10882868B2 (en) 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
WO2016196386A1 (en) 2015-05-30 2016-12-08 Ptc Therapeutics, Inc. Methods for modulating rna splicing
WO2017080967A1 (en) * 2015-11-12 2017-05-18 F. Hoffmann-La Roche Ag Compositions for treating spinal muscular atrophy
EP3377073A4 (en) 2015-11-16 2019-06-26 Ohio State Innovation Foundation METHOD AND COMPOSITIONS FOR TREATING DISORDERS AND DISEASES WITH THE SURVIVAL MOTOR NEURON (SMN) PROTEIN
LT3386511T (lt) 2015-12-10 2021-08-25 Ptc Therapeutics, Inc. Hantingtono ligos gydymo būdai
EP3386978B1 (en) 2015-12-10 2021-01-27 H. Hoffnabb-La Roche Ag Bridged piperidine derivatives
JP6738044B2 (ja) * 2016-07-22 2020-08-12 Jnc株式会社 ベンゾピラン骨格を有する液晶性化合物、液晶組成物、および液晶表示素子
EA201991309A1 (ru) 2016-11-28 2019-11-29 Способы модуляции сплайсинга рнк
EP3634953B1 (en) 2017-06-05 2024-01-03 PTC Therapeutics, Inc. Compounds for treating huntington's disease
KR20200017476A (ko) 2017-06-14 2020-02-18 피티씨 테라퓨틱스, 인크. Rna 스플라이싱의 변경 방법
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
EP3645121A4 (en) 2017-06-28 2021-03-17 PTC Therapeutics, Inc. HUNTINGTON'S DISEASE TREATMENT METHODS
BR122020005073A2 (pt) 2017-08-04 2020-10-13 Skyhawk Therapeutics, Inc. Composto, composição farmacêutica e uso do composto
US20210009590A1 (en) 2018-03-27 2021-01-14 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
EP3814357B1 (en) 2018-06-27 2024-05-01 PTC Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
EP3814360A1 (en) 2018-06-27 2021-05-05 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
CR20210050A (es) * 2018-06-27 2021-06-10 Reborna Biosciences Inc Agente profiláctico o terapéutico para atrofia muscular espinal
KR20210135241A (ko) 2019-02-05 2021-11-12 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
WO2020163544A1 (en) 2019-02-06 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US11129829B2 (en) 2019-06-17 2021-09-28 Skyhawk Therapeutics, Inc. Methods for modulating splicing

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5854142B2 (ja) * 1975-04-16 1983-12-02 株式会社興人 イソカルボスチリル誘導体の製造方法
US5089633A (en) * 1987-04-28 1992-02-18 Georgia Tech Research Corporation Substituted isocoumarins
US6180625B1 (en) * 1998-03-24 2001-01-30 Novo Nordisk A/S Heterocyclic compounds regulating clotting
WO2003004458A1 (en) * 2001-07-03 2003-01-16 Biovitrum Ab New compounds
GB0205281D0 (en) 2002-03-06 2002-04-17 Novartis Ag Organic compounds
US20040077529A1 (en) 2002-06-10 2004-04-22 Per-Fredrik Lehmann Urotensin II receptor agents
AR040350A1 (es) * 2002-06-28 2005-03-30 Vertex Pharma Inhibidores de caspasa y usos de los mismos
JP2004168707A (ja) * 2002-11-20 2004-06-17 Bayer Cropscience Ag イソチアゾリルベンゾオキサジン誘導体および病害防除剤
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
WO2004111014A1 (en) 2003-06-06 2004-12-23 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
WO2006078834A1 (en) 2005-01-21 2006-07-27 Janssen Pharmaceutica N.V. Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
KR100781704B1 (ko) * 2005-04-20 2007-12-03 에스케이케미칼주식회사 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
US8337941B2 (en) 2006-07-27 2012-12-25 The Trustees Of Columbia University In The City Of New York Fluorescent substrates for monoamine transporters as optical false neurotransmitters
KR20080091949A (ko) * 2007-04-10 2008-10-15 에스케이케미칼주식회사 락톤형 피리딘 화합물을 포함하는 허혈성 질환의 예방 및치료용 약학조성물
JP5276878B2 (ja) * 2007-09-27 2013-08-28 富士フイルム株式会社 ベンゾオキサジノン系化合物の製造方法
US8633019B2 (en) * 2008-05-27 2014-01-21 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
WO2010019236A1 (en) 2008-08-13 2010-02-18 Ptc Therapeutics, Inc Methods for treating spinal muscular atrophy
BR112014016287B1 (pt) 2011-12-30 2022-08-09 F. Hoffmann - La Roche Ag Composto e composição farmacêutica
CN104203239B (zh) * 2012-01-26 2017-09-08 Ptc医疗公司 用于治疗脊髓性肌萎缩的化合物
TR201813877T4 (tr) 2012-02-10 2018-11-21 Hoffmann La Roche Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
US9371336B2 (en) 2012-03-01 2016-06-21 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
KR102109992B1 (ko) 2012-03-23 2020-05-13 피티씨 테라퓨틱스, 인크. 척수성 근위축증을 치료하기 위한 화합물

Also Published As

Publication number Publication date
US20150126515A1 (en) 2015-05-07
KR102064624B1 (ko) 2020-01-09
CN104203239B (zh) 2017-09-08
BR112014018027B1 (pt) 2020-10-27
JP6193888B2 (ja) 2017-09-06
KR20140127271A (ko) 2014-11-03
JP2017171667A (ja) 2017-09-28
EP2809322A1 (en) 2014-12-10
EP2809322B1 (en) 2019-05-15
ES2733644T3 (es) 2019-12-02
EA201491412A1 (ru) 2014-12-30
JP2015511224A (ja) 2015-04-16
CA2862084C (en) 2021-05-11
EA028344B1 (ru) 2017-11-30
BR112014018027A8 (pt) 2017-07-11
CA2862084A1 (en) 2013-08-01
HK1202069A1 (en) 2015-09-18
MX2014008875A (es) 2014-10-14
WO2013112788A1 (en) 2013-08-01
EP2809322B9 (en) 2019-10-30
EP2809322A4 (en) 2015-12-23
BR112014018027A2 (es) 2017-06-20
PL2809322T3 (pl) 2019-11-29
US9399649B2 (en) 2016-07-26
CN104203239A (zh) 2014-12-10

Similar Documents

Publication Publication Date Title
PH12018501711A1 (en) Compounds for treating spinal muscular atrophy
MX357834B (es) Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal.
MX2014010406A (es) Compuestos para tratar atrofia muscular espinal.
MX358514B (es) Compuestos para tratar la atrofia muscular espinal.
PH12014502704B1 (en) Compounds and compositions for modulating egfr activity
WO2014052836A3 (en) Methods and compositions for treating infection
GEP201706754B (en) Proliposomal testosterone formulations
MX359769B (es) Metodos para descelularizar huesos.
AU2013225816A8 (en) Compositions and methods for treating Type III Gaucher Disease
MX367393B (es) Composiciones antifungicas para el tratamiento de piel y uñas.
WO2012017321A3 (en) Treatment for dyslipidemia
GEP201706708B (en) Isoxazolidine derivatives
MX356102B (es) Compuestos y métodos para tratar leucemia.
MX2013008559A (es) Derivados de leptina.

Legal Events

Date Code Title Description
FG Grant or registration